Reported 4 days ago
The PGIM Jennison Health Sciences Fund's Q1 2025 investor letter highlights Vertex Pharmaceuticals (NASDAQ:VRTX) for its market leadership in cystic fibrosis therapies and promising developments in acute pain management. Despite a recent share value decline of 5.47% over the past year, Vertex's innovative pipeline and strong clinical trial results suggest significant growth potential. However, the fund acknowledges a preference for certain AI stocks that may offer higher returns in the near term.
Source: YAHOO